254 related articles for article (PubMed ID: 29176689)
21. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
22. miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin.
Bhatlekar S; Manne BK; Basak I; Edelstein LC; Tugolukova E; Stoller ML; Cody MJ; Morley SC; Nagalla S; Weyrich AS; Rowley JW; O'Connell RM; Rondina MT; Campbell RA; Bray PF
Blood; 2020 Oct; 136(15):1760-1772. PubMed ID: 32844999
[TBL] [Abstract][Full Text] [Related]
23. HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling.
Vong P; Messaoudi K; Jankovsky N; Gomilla C; Demont Y; Caulier A; Jedraszak G; Demagny J; Djordjevic S; Boyer T; Marolleau JP; Rochette J; Ouled-Haddou H; Garçon L
J Cell Mol Med; 2023 Jan; 27(2):174-188. PubMed ID: 36578217
[TBL] [Abstract][Full Text] [Related]
24. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
25. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S
Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Jian W; Wei X; Chen L; Wang Z; Sun Y; Zhu S; Lou H; Yan S; Li X; Zhou J; Zhang B
Neurosci Lett; 2017 Sep; 658():114-120. PubMed ID: 28823893
[TBL] [Abstract][Full Text] [Related]
27. Modification of cardiac disease by transgenically altered histone deacetylase 6.
Sanbe A; Inomata Y; Matsushita N; Sawa Y; Hino C; Yamazaki H; Takanohashi K; Takahashi N; Higashio R; Tsumura H; Aoyagi T; Hirose M
Biochem Biophys Res Commun; 2022 Nov; 631():48-54. PubMed ID: 36166953
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice.
Zhou D; Choi YJ; Kim JH
Sci Rep; 2017 Aug; 7(1):8131. PubMed ID: 28811599
[TBL] [Abstract][Full Text] [Related]
29. Deletion of Grin1 in mouse megakaryocytes reveals NMDA receptor role in platelet function and proplatelet formation.
Hearn JI; Green TN; Hisey CL; Bender M; Josefsson EC; Knowlton N; Baumann J; Poulsen RC; Bohlander SK; Kalev-Zylinska ML
Blood; 2022 Apr; 139(17):2673-2690. PubMed ID: 35245376
[TBL] [Abstract][Full Text] [Related]
30. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
31. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Zuo Q; Wu W; Li X; Zhao L; Chen W
Oncol Rep; 2012 Mar; 27(3):819-24. PubMed ID: 22089141
[TBL] [Abstract][Full Text] [Related]
32. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
33. Chaperone-Assisted Mitotic Actin Remodeling by BAG3 and HSPB8 Involves the Deacetylase HDAC6 and Its Substrate Cortactin.
Luthold C; Varlet AA; Lambert H; Bordeleau F; Lavoie JN
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375626
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of histone deacetylase reduces lipopolysaccharide-induced-inflammation in primary mammary epithelial cells by regulating ROS-NF-кB signaling pathways.
Wang J; Zhao L; Wei Z; Zhang X; Wang Y; Li F; Fu Y; Liu B
Int Immunopharmacol; 2018 Mar; 56():230-234. PubMed ID: 29414656
[TBL] [Abstract][Full Text] [Related]
35. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
36. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.
McLendon PM; Ferguson BS; Osinska H; Bhuiyan MS; James J; McKinsey TA; Robbins J
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5178-86. PubMed ID: 25404307
[TBL] [Abstract][Full Text] [Related]
37. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin.
Kaluza D; Kroll J; Gesierich S; Yao TP; Boon RA; Hergenreider E; Tjwa M; Rössig L; Seto E; Augustin HG; Zeiher AM; Dimmeler S; Urbich C
EMBO J; 2011 Aug; 30(20):4142-56. PubMed ID: 21847094
[TBL] [Abstract][Full Text] [Related]
38. Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Vergani B; Sandrone G; Marchini M; Ripamonti C; Cellupica E; Galbiati E; Caprini G; Pavich G; Porro G; Rocchio I; Lattanzio M; Pezzuto M; Skorupska M; Cordella P; Pagani P; Pozzi P; Pomarico R; Modena D; Leoni F; Perego R; Fossati G; Steinkühler C; Stevenazzi A
J Med Chem; 2019 Dec; 62(23):10711-10739. PubMed ID: 31710483
[TBL] [Abstract][Full Text] [Related]
39. Deacetylation of α-tubulin and cortactin is required for HDAC6 to trigger ciliary disassembly.
Ran J; Yang Y; Li D; Liu M; Zhou J
Sci Rep; 2015 Aug; 5():12917. PubMed ID: 26246421
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
